Viennese biotech company Marinomed demonstrates the benefits of its patented Marinosolv® technology
By: Marinomed Biotech AG
• Bioavailability in the eye up to 15 times higher under laboratory conditions when compared to commercially available alternative treatments
• Findings published in the European Journal of Pharmaceutics and Biopharmaceutics
• Clinical trial for Tacrosolv, a tacrolimus-based product candidate against allergic conjunctivitis, planned for 2019
Vienna, 28 November 2018 – Marinomed Biotech AG (Marinomed) – an established Viennese biopharmaceutical company with a global presence – has published the results of scientific investigations that clearly demonstrate the benefits of its Marinosolv® technology platform. The study, which is available to read now in the European Journal of Pharmaceutics and Biopharmaceutics, shows that the solubility of the immunomodulator tacrolimus is 200 times greater in Marinosolv® than in water. This higher solubility could offer significant advantages for producers of tacrolimus-based medicines as well as patients – advantages which Marinomed is already exploiting with the development of Tacrosolv, its product candidate for the treatment of allergic conjunctivitis and dry eye syndrome.
Marinomed's Chief Executive Officer Dr. Andreas Grassauer commented: "These are important results in terms of demonstrating the effectiveness of our Marinosolv® technology platform. This is the basis of our two product candidates Budesolv and Tacrosolv which we are developing for rapidly growing billion-dollar markets."
Budesolv, a solubilized version of the corticosteroid budesonide developed for the treatment of allergic rhinitis, is already being tested in a pivotal clinical phase III trial, and Tacrosolv is expected to reach the phase II trial stage for the treatment of conjunctivitis in 2019. The next step for Tacrosolv will then be a pivotal phase III trial for allergic conjunctivitis and dry eye syndrome.
The Marinosolv® platform behind both product candidates was developed by Marinomed in 2015. At present, 40% of approved medicines and nearly 90% of therapeutic molecules currently in the research pipelines of pharmaceutical companies are poorly soluble.* Marinosolv® makes it possible to improve the water solubility of otherwise hardly soluble compounds – resulting in a lower drug dosage and a faster action. The Marinosolv® platform therefore opens up opportunities for the development of products that offer improved local availability of active ingredients in sensitive parts of the body such as the eyes and nose. The impact on the rest of the body is subsequently lower, meaning side effects could be reduced. Marinosolv® also enables preservative-
The data on solubilized tacrolimus published by Marinomed's research team demonstrates how effectively Marinosolv® can function. In addition to the improved water solubility of the immunomodulator using Marinosolv®, bioavailability was also significantly higher as a result. Different concentrations of tacrolimus were also tested using various forms of administration in the cornea of a model system. In comparison to tacrolimus applications that are already commercially available, the researchers found a 15-fold increase in concentration of the drug in the cornea when it was dissolved using Marinosolv®. Unlike the currently available products, which are taken orally or by injection, it could be simply administered as eye drops. No local, systemic side effects or histopathological changes were found. An additional finding was that tacrolimus, when dissolved in Marinosolv®, permeated into the posterior part of the eye in higher concentrations than the currently available products administered orally or by injection – a result which points to the suitability of Tacrosolv for the treatment of certain other ocular indications.
Commenting on Marinomed's development objectives for its proprietary platforms, Dr. Grassauer said: "We are planning to capitalize on Marinosolv® to enter the multi-billion-
* source: Acta Pharmaceutica Sinica B, September 2015 issue
About Marinomed Biotech AG
Headquartered in Vienna, biopharmaceutical company Marinomed Biotech AG focuses on developing innovative products for the airway and eye disease segment using patented technology platforms. The Carragelose®
Dr. Eva Prieschl-Grassauer
Chief Scientific Officer
Marinomed Biotech AG
1210 Vienna, Austria
Tel. +43 (0)1 25077 4460
1040 Vienna, Austria
Tel. +43 (0) 1 504 69 87 331
Dr. Till C. Jelitto
PR&D – Public Relations for Research & Education
1090 Vienna, Austria
Tel. +43 (0)1 505 7044
Mobile: +43 (0)664 226 9364